The British Journal of Psychiatry 174: 173-178 (1999)
© 1999 The Royal College of Psychiatrists

Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism

KE Hayford, CA Patten, TA Rummans, DR Schroeder, KP Offord, IT Croghan, ED Glover, DP Sachs and RD Hurt
Department of Psychiatry, Mayo Clinic, Rochester, MN 55905, USA.

BACKGROUND: A past history of major depression or alcoholism has been associated with poorer smoking treatment outcomes. AIM: To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence. METHOD: Data were drawn from a multicentre trial of bupropion for smoking cessation. Smokers (n = 615) received placebo or bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD). The primary outcome was the point prevalence smoking abstinence at the end of treatment and at one year. The Beck Depression Inventory (BDI) was used to assess depressive symptoms. RESULTS: A significant dose-response effect of bupropion for smoking cessation was found. This was independent of history of major depression or alcoholism. Among those continuously abstinent from smoking for two weeks following TQD, an increase in BDI score was associated with a return to smoking at end of treatment. CONCLUSIONS: Bupropion is efficacious for smoking cessation independently of a former history of major depression or alcoholism. Increases in depressive symptoms during an initial period of abstinence are associated with a return to smoking.

This article has been cited by other articles:

				J. Campion, K. Checinski, and J. Nurse Review of smoking cessation treatments for people with mental illness Advan. Psychiatr. Treat., May 1, 2008; 14(3): 208 - 216. [Abstract] [Full Text] [PDF]

				R. F. Yoshimura, D. J. Hogenkamp, W. Y. Li, M. B. Tran, J. D. Belluzzi, E. R. Whittemore, F. M. Leslie, and K. W. Gee Negative Allosteric Modulation of Nicotinic Acetylcholine Receptors Blocks Nicotine Self-Administration in Rats J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 907 - 915. [Abstract] [Full Text] [PDF]

				J. Littleton, S. Barron, M. Prendergast, and S. J. Nixon Smoking kills (alcoholics)! shouldn't we do something about it? Alcohol Alcohol., May 1, 2007; 42(3): 167 - 173. [Abstract] [Full Text] [PDF]

				J. L. Heffner, S. W. Barrett, and R. M. Anthenelli Predicting Alcohol Misusers' Readiness and Ability to Quit Smoking: a Critical Review Alcohol Alcohol., May 1, 2007; 42(3): 186 - 195. [Abstract] [Full Text] [PDF]

				R. F. Leeman, C. J. Huffman, and S. S. O'Malley Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review Alcohol Alcohol., May 1, 2007; 42(3): 196 - 206. [Abstract] [Full Text] [PDF]

				A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]

				S Tonstad, C Farsang, G Klaene, K Lewis, A Manolis, A.P Perruchoud, C Silagy, P.I van Spiegel, C Astbury, A Hider, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Eur. Heart J., May 2, 2003; 24(10): 946 - 955. [Abstract] [Full Text] [PDF]

				N. el-Guebaly, J. Cathcart, S. Currie, D. Brown, and S. Gloster Smoking Cessation Approaches for Persons With Mental Illness or Addictive Disorders Psychiatr Serv, September 1, 2002; 53(9): 1166 - 1170. [Abstract] [Full Text] [PDF]

				J. E. Slemmer, B. R. Martin, and M. I. Damaj Bupropion Is a Nicotinic Antagonist J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 321 - 327. [Abstract] [Full Text]

				J. Britton and M. J Jarvis Bupropion: a new treatment for smokers BMJ, July 8, 2000; 321(7253): 65 - 66. [Full Text]

				J.K. Neumann, B. Peeples, J. East, and A. R. Ellis Nicotine reduction : effectiveness of bupropion The British Journal of Psychiatry, July 1, 2000; 177 (1): 87 - 88. [Full Text] [PDF]

				R. D. Hurt, G. A. Croghan, S. D. Beede, T. D. Wolter, I. T. Croghan, and C. A. Patten Nicotine Patch Therapy in 101 Adolescent Smokers: Efficacy, Withdrawal Symptom Relief, and Carbon Monoxide and Plasma Cotinine Levels Arch Pediatr Adolesc Med, January 1, 2000; 154(1): 31 - 37. [Abstract] [Full Text] [PDF]